When Daniel Haders, Ph.D., was working in venture capital, he was on the hunt for an AI-driven drug discovery company that ...
Ligand-based drug design combines AI and QSAR modeling to prioritize drug candidates, minimizing preclinical failures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results